DPZ, as an acetylcholinesterase inhibitor, has been reported to improve cognitive impairment and global function in patients with mild to moderately severe Alzheimer’s disease [13,38]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.